ClinicalTrials.gg
CompletedNCT06816030Updated Apr 16, 2026

A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

A Phase 1 interventional study of MK-4482 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Jun 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.

Enrollment
14th of 14
16 · median 275
Started
2023
the only one that year
Phase 1
Only one
of the 14
Registered
14th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing molnupiravir in COVID-19, this one is the 14th largest by enrollment, is the only one that started in 2023, is the only one in phase 1, and was the 14th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About molnupiravir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing molnupiravir in COVID-19, or all of them as a file.
02

Study summary

The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Coronavirus Disease (COVID-19)
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

- Has a (BMI) of 19 to 24 weight (kg)/height (m)2, inclusive, and body weight of ≥ 50 kg at the screening visit.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of abnormalities or diseases.
  • Has history of cancer.
  • Has a history of significant multiple and/or severe allergies.
  • Had any major surgery.
  • Has participated in another study within 3 months prior to the screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    MK-4482

    Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.

    Drug: MK-4482

Interventions

  • Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.

06

What researchers measure

Primary outcomes

  1. The Maximum Observed Plasma Concentration (Cmax) After Single Oral Dose of MK-4482 in Period 1

    Cmax of N-hydroxycytidine (NHC) after a single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Single Oral Dose of MK-4482 in Period 1.

    Tmax of NHC following single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  3. Elimination Half Life (T1/2) After Single Oral Dose of MK-4482 in Period 1

    T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after a single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  4. Apparent Total Clearance (CL/F) After Single Oral Dose of MK-4482 in Period 1

    CL/F of NHC from plasma after single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  5. Apparent Volume of Distribution (Vz/F) After Single Oral Dose of MK-4482 in Period 1

    Vz/F of NHC during terminal phase after single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  6. Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Single Oral Dose of MK-4482 in Period 1

    This is a measure of the average amount of NHC in the plasma over a period of 12 hours after single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  7. Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration (AUC0-last) After Single Oral Dose of MK-4482 in Period 1

    AUC0-last of NHC following a single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  8. Area Under The Plasma Concentration Versus Time Curve From Time Zero (pre-dose) to Extrapolated Infinite Time (AUC0-inf) After Single Oral Dose of MK-4482 in Period 1

    AUC0-inf of NHC after single oral dose of MK-4482 in period 1.

    Time frame: At designated time points up to 72 hours post-dose

  9. The Maximum Observed Plasma Concentration (Cmax) After Multiple Oral Doses of MK-4482 in Period 2

    Cmax of NHC after multiple oral doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Multiple Oral Doses of MK-4482 in Period 2

    Tmax of NHC following multiple oral doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  11. Elimination Half Life (T1/2) After Multiple Oral Doses of MK-4482 in Period 2

    T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after multiple oral doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  12. Clearance at Steady State (CLss/F) After Multiple Oral Doses of MK-4482 in Period 2

    CLss/F of plasma NHC following multiple doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  13. Apparent Volume of Distribution (Vz/F) After Multiple Oral Doses of MK-4482 in Period 2

    Vz/F of NHC during terminal phase after multiple doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  14. Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Multiple Oral Doses of MK-4482 in Period 2

    This is a measure of the average amount of NHC in the plasma over a period of 12 hours after multiple oral doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  15. The Minimum Concentration (Ctrough) After Multiple Oral Doses of MK-4482 in Period 2

    Ctrough of NHC that occurred following multiple doses of MK-4482 in period 2.

    Time frame: At designated time points up to 72 hours post-dose

  16. Accumulation Ratio on Cmax After Multiple Oral Doses of MK-4482 in Period 2

    The maximum concentration at steady state following multiple doses of MK-4482 in period 2 divided by the maximum concentration following the initial dosing in Period 1.

    Time frame: At designated time points up to 72 hours post-dose

  17. Accumulation Ratio on AUC0-12hr After Multiple Oral Doses of MK-4482

    The AUC0-12hr at steady state following multiple doses of MK-4482 in period 2 divided by the AUC0-12hr following the initial dosing in Period 1.

    Time frame: At designated time points up to 72 hours post-dose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to ~ 5.5 weeks

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to ~ 5.5 weeks

07

Study locations

1 site
  • Peking University Third Hospital (Site 0001)
    Beijing, Beijing Municipality 100191, China
08

References and documents

Publications

  • Zhu J, Zhang D, Liu Z, Yan B, Zang Y, Zhao W, Sun F, Maas BM, Cheng MH, Stoch SA, Li H. Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study. Clin Transl Sci. 2026 Apr;19(4):e70481. doi: 10.1111/cts.70481. PubMed 41904711 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2023, 1 month.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartActual
Jun 28, 2023
Primary completionActual
Aug 5, 2023
CompletionActual
Aug 5, 2023
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816030
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Jun 28, 2023
Primary completion
Aug 5, 2023
Completion
Aug 5, 2023
Last update
Apr 16, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion